Prognostic value of three different lymph node staging systems in the survival of patients with gastric cancer following D2 lymphadenectomy by unknown
ORIGINAL ARTICLE
Prognostic value of three different lymph node staging systems
in the survival of patients with gastric cancer following D2
lymphadenectomy
Chen Jian-hui1,2 & Cai Shi-rong1,2 & Wu Hui1,2 & Chen Si-le1,2 & Xu Jian-bo1,2 &
Zhai Er-tao1,2 & Chen Chuang-qi1,2 & He Yu-long1,2
Received: 17 August 2015 /Accepted: 1 October 2015 /Published online: 24 February 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The log odds of positive lymph nodes (LODDS)
was defined as the log of the ratio between the number of
positive lymph nodes and the number of negative lymph
nodes, which is a novel and promising nodal staging system
for gastric cancer. Here, we aimed to compare the prognostic
effect of pN, lymph node ratio (LNR) and LODDS. The as-
sociation between overall survival and pN, LNR and LODDS
was retrospectively analysed. The discriminatory ability and
monotonicity of gradients (linear trend χ2 score), homogene-
ity ability (likelihood ratio test) and prognostic stratification
ability (Akaike information criterion [AIC] and receiver oper-
ating characteristic [ROC] curve) were compared among three
lymph node staging systems. The pN, LNR and LODDSwere
all identified as independent prognostic factors for gastric can-
cer patients in the multivariate analysis. LODDS showed the
best prognostic performance (linear trend χ2 score 266.743,
likelihood ratio χ2 test score 427.771, AIC value 5670.226,
area under the curve (AUC) 0.793), followed by LNR and pN.
In patients with different levels of retrieved lymph nodes (≤10,
11–14, 15–25 and >25), LODDS was the most powerful for
prognostic prediction and discrimination of the heterogeneity
among the subgroups. Significant differences in survival were
observed among patients in different LODDS subgroups after
being classified according to the pN and LNR classifications.
LODDS appears to be a more powerful system for predicting
the overall survival of gastric cancer patients, as compared to
LNR and pN, and may serve as an alternative nodal staging
system for gastric cancer.
Keywords Log odds of positive lymph nodes . Lymph node
ratio . Nodal system . Prognosis . Gastric cancer
Introduction
According to the GLOBOCAN 2012 database, 952,000 new
cases of gastric cancer and 723,000 cases of gastric cancer-
related death are reported worldwide, which correspond to the
total malignant cases of 8.5 and 10.1 %, respectively. Lymph
node metastasis is known to be one of the most important
prognostic factors for gastric cancer. Although the lymph node
staging system, based on the extent of lymph node metastasis,
was abandoned in the latest guideline of the Japanese Gastric
Cancer Association (JGCA) [1], the prognostic ability of the
lymph node staging system of the Union for International
Cancer Control (UICC) remains controversial. Some authors
indicated that the latest lymph node classification, as part of
UICC staging, is influenced by the number of retrieved lymph
nodes [2]. Moreover, certain studies suggested that the ratio-
based lymph node system, which evaluates the ratio of meta-
static lymph nodes and total retrieved lymph nodes, was the-
oretically superior to the involved number-based lymph node
system, as the former system considers information of both
metastatic and the total retrieved lymph nodes [3, 4]. The
favourable results obtained from a comparison of survival
with the ratio-based lymph node system suggest that this sys-
tem may serve as an alternative to the traditional one.
However, some studies indicated that patients with the same
LNR staging had different survival outcomes, along with
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changes in the total number of retrieved lymph nodes, partic-
ularly when the LNR value was 0 or 1 [5].
Log odds of positive nodes (LODDS) is a novel, promising
lymph node staging system and is defined as the log of the
ratio of the number of positive lymph nodes and the total
number of retrieved lymph nodes. The LODDS system has a
better discrimination ability for patients without metastatic
lymph nodes and has been considered as a more reliable meth-
od than the pN or LNR systems for prognostic evaluation in
gastric cancer patients [6, 7]. Till now, there is no study to
compare the prognostic significance of pN, LNR and
LODDS systems together in Asian patients after D2
lymphadenectomy.
In the present study, we aimed to compare the prognostic
performance of the pN, LNR and LODDS lymph node staging
systems and to determine the most appropriate lymph node




Between January 1994 and December 2008, all the cases
diagnosed with gastric adenocarcinoma after radical sur-
gery in the Department of Gastrointestinal Surgery of the
First Affiliated Hospital, Sun Yat-sen University, China,
were retrospectively analysed. The eligibility criteria were
as follows: patients with gastric adenocarcinoma diag-
nosed via a histopathologic examination; patients receiving
R0 resection and D2 lymphadenectomy, or extensive
lymphadenectomy if necessary; patient death due to cancer
and patients with complete follow-up data. The exclusion
criteria were as follows: patients with a history of malig-
nant tumours at other sites or gastric stump cancer. patients
who were diagnosed with distant metastasis preoperatively
or during the operation, patients who received neoadjuvant
chemotherapy or radiochemotherapy and patients who died
due to postoperative complications. In total, 935 patients
were included in this study.
Written informed consent was obtained from all the pa-
tients preoperatively. The study was approved by the Ethics
Committees of The First Affiliated Hospital of Sun Yat-sen
University.
All the cases were followed up every 3 months in the first
2 years, every half year in the after 3 years and every year
thereafter. Follow-up program consisted of physical examina-
tion, serum tumour markers, chest X-ray, annual gastroscope,
abdominal CT scan or ultrasound every 6 months. The last
follow-up was in December 2014. The median follow-up time
was 56 months.
Lymph node classifications
Lymph nodes were classified according to the seventh edition
of the UICC/AJCC tumour-node-metastasis (TNM) system,
based on the number of metastatic lymph nodes: N0, negative;
N1, 1–2 positive lymph nodes; N2, 3–6 positive lymph nodes;
N3, >6 positive lymph nodes. The LNR was defined as the
ratio between the metastatic lymph nodes and total retrieved
lymph nodes. The LNR ranged from 0 to 1 and was stratified
at intervals of 0.1; it was used to compare the overall survival
among each interval and among adjacent subgroups with sim-
ilar survival outcomes. The LNR system was classified as
follows: LNR0, 0; 0.01<LNR1≤0.1; 0.1<LNR2≤0.25 and
LNR3 > 0.25. LODDS was defined as log ([pLN+ 0.5] /
[nLN+0.5]), where pLN is the number of positive lymph
nodes and nLN is the number of negative lymph nodes; 0.5
was added to both the numerator and denomination to avoid
singularity. A similar method was performed to stratify
LODDS, with an interval of 0.5. Thus, LODDS was classified
as follows: LODDS1 ≤ −1.5, −1.5 < LODDS2 ≤ −1.0,
−1.0<LODDS3≤0.0 and LODDS4>0.0.
Statistical analysis
The overall survival rate was calculated according to the life
table method, and the log-rank test was used to assess statistical
differences between groups. Survival curves were established
using the Kaplan-Meier method. All the parameters that were
statistically significant in the univariate analysis were included
in the multivariate Cox proportional hazard model. With the
Cox proportional hazard model, the likelihood ratio (χ2) test
was used to measure homogeneity between groups, whereas
the Akaike information criterion (AIC) was adopted to mini-
mise any potential bias when comparing different prognostic
systems. The AIC was defined by a −2 log maximum likeli-
hood +2, multiplied by the number of parameters in the model.
The discriminatory ability and monotonicity of gradients were
measured using the linear trend χ2 test. The accuracy of the
prognostic evaluation of different staging systems was com-
pared using receiver operating characteristic (ROC) curve anal-
ysis and the area under the curve (AUC). The accepted level of
statistical significance was defined as P<0.05. The statistical
analysis was performed using the SPSS 18.0 statistical package
(SPSS Inc., Chicago, IL).
Results
Clinicopathological characteristics and survival analysis
In total, 935 patients were enrolled, including 636 men and
299 women, with a mean age of 57.5 years (range, 24–
87 years). The gastric cancer was located in the lower part of
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the stomach (44.7 %) in most cases, followed by the upper
portion (31.6 %), middle portion (21.7 %) and the entire stom-
ach (2.0 %). Moreover, the average number of total retrieved
lymph nodes was 24.9 per case (range, 0–140). The mean
number of involved lymph nodes in our cohort was 4.61
(range, 0–124). Among 18.6 % of the patients, lymph node
retrieval was insufficient. The 5-year survival rate of our co-
hort was 54.0 %, with a median overall survival time of
53.3 months (range, 1.3–148.4 months). Table 1 shows the
demographics and survival results of our study.
Table 1 Clinicopathological
characteristics and survival
analysis of 935 patients with
gastric cancer following radical
gastrectomy
Variable Patients (%) 5-year survival rate χ2 value (log-rank test) P value
Age (years) 7.6767 0.006
<60 526 (56.3 %) 57.2 %
≧60 409 (43.7 %) 49.9 %
Sex 3.190 0.074
Male 636 (68.0 %) 52.0 %
Female 299 (32.0 %) 58.2 %
Tumour site 30.575 <0.001
Upper 295 (31.6 %) 43.1 %
Middle 203 (21.7 %) 60.1 %
Lower 418 (44.7 %) 60.0 %
Whole 19 (2.0 %) 26.3 %
Tumour size 79.694 <0.001
<5 cm 613 (65.6 %) 63.4 %
≧5 cm 322 (34.4 %) 36.0 %
Gross type 69.323 <0.001
Borrmann I + II 351 (37.5 %) 71.5 %
Borrmann III + IV 584 (62.5 %) 43.4 %
Degree of differentiation 12.898 <0.001
Well/moderately 340 (36.4 %) 61.1 %
Pooly/undifferentiated 595 (63.6 %) 50.0 %
Seventh T stage (UICC) 159.378 <0.001
T1 162 (17.3 %) 86.4 %
T2 125 (13.4 %) 74.3 %
T3 330 (35.3 %) 52.4 %
T4 318 (34.0 %) 31.1 %
Seventh N stage (UICC) 281.440 <0.001
N0 364 (38.9 %) 81.6 %
N1 172 (18.4 %) 56.4 %
N2 199 (21.3 %) 40.2 %
N3 200 (21.4 %) 18.0 %
LNR stage 368.726 <0.001
LNR0 364 (38.9 %) 81.6 %
LNR1 143 (15.3 %) 63.6 %
LNR2 197 (21.1 %) 42.6 %
LNR3 231 (24.7 %) 14.3 %
LODDS stage 428.720 <0.001
LODDS1 277 (29.6 %) 87.0 %
LODDS2 170 (18.2 %) 65.9 %
LODDS3 385 (41.2 %) 37.7 %
LODDS4 103 (11.0 %) 7.0 %
Number of LN retrieved 16.801 <0.001
<15 174 (18.6 %) 42.0 %
≧15 761 (81.4 %) 56.7 %
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Survival impact of pN, R stage and LODDS
The survival curves of patients according to pN, LNR and
LODDS were all significantly different (Fig. 1a–c) (all,
P<0.001). In the univariate analysis, age, tumour location,
tumour size, gross type, histological type, number of retrieved
lymph nodes, pN, LNR and LODDS were significantly cor-
related with overall survival (Table 2). All the potential prog-
nostic factors identified in the univariate analysis were includ-
ed in the multivariate analysis. All the three lymph node stag-
ing systems (pN, LNR and LODDS) were identified as sig-
nificantly independent prognostic factors of overall survival in
our cohort (Table 3).
Comparison of prognostic ability among pN, R stage
and LODDS
To identify the most appropriate system of representing lymph
node involvement for the evaluation of overall survival in gas-
tric cancer patients, we adopted the linear trend χ2 score to
evaluate the discriminatory ability and monotonicity of gradi-
ents, the likelihood ratio (χ2) test to assess homogeneity ability
and AIC value and ROC curve to compare the prognostic abil-
ity among the systems. We observed that LODDS had the
highest linear trend χ2 score and likelihood ratio (χ2) test score,
lowest AIC value and largest AUC (Table 4). Therefore, we
considered that the LODDS was superior to LNR and pN.
To elucidate the reason for the superiority of LODDS com-
pared to pN and LNR, we created scatter plots of the relation-
ship between LODDS and the number or ratio of lymph node
involvement. As shown in Fig. 2a, b, the LODDS value in-
creased with the number and the ratio of metastatic lymph
nodes, indicating close relationships between LODDS and
pN, as well as LNR. However, these correlations were not
linear. When the number of lymph nodes involved was ≤10
or when the ratio of lymph node metastasis was <0.2, the
curves of pN and LNR increased at a slower rate as compared
Fig. 1 Kaplan-Meier analysis of overall survival (OS) for cases with
gastric cancer according to different lymph node staging systems: a
survival curves of patients according to the pN system, b survival
curves of patients according to the LNR system and c survival curves
of patients according to the LODDS system
Table 2 Univariate analysis of overall survival in gastric cancer
Parameters χ2 value Hazard
ratio
95 % CIa P value
Age 7.619 1.293 1.077–1.551 0.006
Gender 3.183 0.074
Tumour location 29.540 <0.001
Upper
Middle 12.393 0.632 0.489–0.816 <0.001
Lower 17.246 0.645 0.525–0.794 <0.001
Whole 3.480 1.679 0.974–2.894 0.062
Tumour size 75.377 2.251 1.874–2.703 <0.001
Gross type 65.028 2.393 1.936–2.959 <0.001
Histological type 12.735 1.430 1.175–1.741 <0.001
T stage 134.757 <0.001
T1
T2 4.773 1.716 1.057–2.787 0.029
T3 42.484 3.645 2.470–5.377 <0.001
T4 91.655 6.449 4.403–9.446 <0.001
Insufficient retrieved
lymph nodes
16.484 0.637 0.512–0.792 <0.001
pN 101.762 <0.001
pN0 (reference)
pN1 11.413 1.716 1.254–2.347 0.001
pN2 37.078 2.461 1.842–3.289 <0.001
pN3 94.807 4.255 3.161–5.648 <0.001
rN 191.740 <0.001
rN0 (reference)
rN1 20.962 2.407 1.653–3.506 <0.001
rN2 70.592 4.050 2.922–5.612 <0.001




LODDS2 27.166 2.697 1.857–3.917 <0.001
LODDS3 123.286 5.777 4.239–7.874 <0.001
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to the LODDS, indicating that LODDS could be superior to
pN and LNR in the prediction of long-term overall survival of
the cases mentioned above. Moreover, when the ratio of
lymph node metastasis was 0 or 1, the LODDS score was
heterogeneous, indicating that the LODDS system had the
potential to indicate different survival outcomes for patients
with the same LNR stage, especially for cases with an LNR
score of 0 or 1.
Correlation among the total number of retrieved lymph
nodes, pN, LNR and LODDS
APearson test was conducted to evaluate the correlation of the
total number of retrieved lymph nodes with the pN, LNR and
LODDS systems. A strong relationship was observed between
the total number of retrieved lymph nodes and the number or
ratio of metastatic lymph nodes (r = 0.214 and 0.077,
Table 3 Multivariate analysis of overall survival in gastric cancer for the different lymph node staging systems
Parameters Multivariate analysis 1 Multivariate analysis 2 Multivariate analysis 3
HR 95 % CIa p Value HR 95 % CIa p Value HR 95 % CIa P value







Tumour size 1.320 1.087–1.603 0.005 1.257 1.034–1.527 0.021




T2 1.093 0.664–1.799 0.728 1.070 0.648–1.765 0.792 1.029 0.625–1.693 0.911
T3 1.761 1.150–2.694 0.009 1.722 1.127–2.633 0.012 1.818 1.197–2.759 0.005
T4 2.224 1.440–3.433 <0.001 2.173 1.409–3.350 <0.001 2.363 1.550–3.603 <0.001
Insufficient retrieved lymph nodes 0.488 0.389–0.612 <0.001 0.622 0.499–0.776 <0.001 0.748 0.597–0.938 <0.001
pN <0.001
pN0 (reference)
pN1 1.697 1.241–2.320 0.001
pN2 2.610 1.951–3.491 <0.001
pN3 4.987 3.704–6.714 <0.001
rN <0.001
rN0 (reference)
rN1 1.617 1.142–2.29 0.007
rN2 2.486 1.843–3.353 <0.001
rN3 5.702 4.280–7.596 <0.001
LODDS <0.001
LODDS1 (reference)
LODDS2 2.144 1.457–3.153 <0.001
LODDS3 3.840 2.765–5.333 <0.001
LODDS4 12.035 8.234–17.590 <0.001
CIa confidence interval
Table 4 Prognostic ability
comparison among the different
lymph node staging systems for
gastric cancer
Linear trend χ2 score Likelihood ratio χ2 test AIC value ROC area
Seventh UICC pN 215.021 280.826 5769.037 0.767
rN 262.177 367.908 5706.294 0.793
LODDS 266.743 427.771 5670.226 0.793
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P<0.001 and 0.018, respectively). However, there was no
association between the number of retrieved lymph nodes
and LODDS (r=−0.038, P=0.251). The results of Pearson
analysis indicated that LODDS was positively correlated with
pN and LNR (r=0.868 and 0.888, P<0.001 and <0.001, re-
spectively), whereas a strong relationship was present be-
tween pN and LNR (r=0.938, P<0.001).
Evaluation of the prognostic value of different lymph node
staging systems with different levels of retrieved lymph
nodes
To assess the prognostic abilities of pN, LNR and LODDS
with different levels of retrieved lymph nodes, all the patients
were divided into four groups according to the number of
retrieved lymph nodes: group 1 (≤10, n=93), group 2 (11–
14, n= 81), group 3 (15–25, n= 405) and group 4 (>25,
n=356). As shown in Table 5, pN, LNR and LODDS showed
prognostic stratification abilities among the different sub-
groups. We further compared the prognostic performance
among the groups. We noted that in all four groups, the
LODDS system had the highest linear trend χ2 score, likeli-
hood ratio (χ2) test score and lowest AIC value, followed by
the LNR system and pN system. Similarly, the LODDS sys-
tem had the largest AUC in group 1 and group 3. However, in
group 2 and group 4, the LNR system had the largest AUC,
followed by the LODDS and pN systems (Table 6).
Survival analysis of the pN and LNR subgroups according
to the LODDS stratification
To evaluate the survival impact of the LODDS stratification as
per the pN and LNR systems, all the distinct prognostic co-
horts stratified according to the pN or LNR systems were
analysed based on different LODDS stratifications. We ob-
served that the LODDS could discriminate among N0, N1,
N2 and N3, regardless of whether the pN or LNR system
was used, suggesting that LODDS had excellent prognostic
discriminatory ability to assess the current lymph node sys-
tem. All the survival data and statistical results were shown in
Table 7.
Discussion
Information on lymph node involvement in gastric cancer has
a great clinical impact on treatment decisions and survival
assessment. The number-based lymph node staging system
of UICC classification (seventh edition) was widely used, al-
though a principle flaw is that the prognostic accuracy is in-
fluenced by the number of total retrieved lymph nodes [8, 9].
The most recent NCCN guideline recommends that D2
lymphadenectomy should be used to remove an adequate
number of lymph nodes (no less than 15); however, some
studies reported that ≥15 lymph nodes are harvested in only
29 and 60.2 % of cases in the USA [10] and China [11].
Moreover, the optimal number of retrieved lymph nodes to
avoid stage migration remains unclear in some studies [12,
13]. Hence, in cases where the number of tested lymph nodes
was insufficient, the staging migration phenomenon may
occur.
The LNR system considers both the information of nodal
involvement and total lymph nodes tested and can theoretical-
ly overcome the limitations of number-based nodal system.
Most authors indicated that LNR was superior to the pN sys-
tem due to the presence of a larger power for minimising
staging migration [14]. A recent large cohort study (nearly
9000 cases) on gastric cancer in Korea [15] concluded that
Fig. 2 Scatter plots of the relationship between LODDS and the number or ratio of lymph nodes involved: a scatter plots of the relationship between
LODDS and the number of metastatic lymph nodes and b scatter plots of the relationship between LODDS and LNR
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the LNR system is a better alternative for predicting long-term
survival and compensating for the stage migration effect.
However, due to some limitations, it cannot be considered as
an alternative to the current pN staging. First, there is no dif-
ference among the patients with negative lymph nodes be-
tween the pN and LNR systems, indicating that LNR does
not have the ability to distinguish the difference in survival
in pN0 patients. Moreover, the cut-off value of LNR reported
in several studies is varied [14, 16, 17]. In addition, the pa-
tients in the same LNR stage may have different survival
outcomes, with a different number of tested lymph nodes [18].
LODDS—a novel system for assessing the status of lymph
node involvement—is an alternative option for the evaluation
of metastatic lymph nodes to predict overall survival; however,
this system has only been investigated in cases of colon cancer
and breast cancer. Following the report of Sun [6] who
emphasised the favourable prognostic impact of LODDS in
gastric cancer, some studies in China and North America have
validated its use for prognostic purposes. Another study [11]
proposed a new tumour-LODDS-metastasis (TLM) classifica-
tion, which was based on the LODDS system, and was superior
to the TNM and tumour-ratio-metastasis (TRM) classifications
in the prognostic assessment of cases following D2 lymphade-
nectomy. Some studies did not note any superiority of LODDS
over the pN or LNR systems [10, 19]. Yu [20] indicated the
LODDS system may reflect a false survival outcome for pa-
tients with gastric cancer, with a reduced true hazard ratio of the
N status against survival. An ideal lymph node staging system
should satisfy three conditions [21]: decreased patient survival
with increasing stage (monotonicity), similar survival within a
group (homogeneity) and difference in survival between groups
(distinctiveness). To our knowledge, the present study is the
Table 5 Evaluation of the prognostic value of the different lymph node
systems with different levels of retrieved lymph nodes
Number 5-year survival
rate
χ2 value P value
Retrieved LN (≦10) 93
Seventh UICC pN staging 9.792 0.020
pN0 47 (50.5 %) 61.7 %
pN1 25 (26.9 %) 40.0 %
pN2 18 (19.4 %) 33.3 %
pN3 3 (3.2 %) 0.0 %
pN ratio 39.029 <0.001
rN0 47 (50.5 %) 74.5 %
rN1 5 (5.4 %) 40.0 %
rN2 15 (16.1 %) 33.3 %
rN3 26 (28.0 %) 11.5 %
LODDS 64.853 <0.001
LODDS1 4 (4.3 %) 100.0 %
LODDS2 42 (45.2 %) 73.8 %
LODDS3 35 (37.6 %) 28.6 %
LODDS4 12 (12.9 %) 0.0 %
Retrieved LN (11–14) 81
Seventh UICC pN staging 33.848 <0.001
pN0 34 (42.0 %) 91.2 %
pN1 18 (22.2 %) 27.8 %
pN2 16 (19.8 %) 25.0 %
pN3 13 (16.0 %) 23.1 %
pN ratio 61.503 <0.001
rN0 34 (42.0 %) 91.2 %
rN1 9 (11.1 %) 55.6 %
rN2 18 (22.2 %) 33.3 %
rN3 20 (24.7 %) 5.0 %
LODDS 66.012 <0.001
LODDS1 3 (3.7 %) 100.0 %
LODDS2 31 (38.3 %) 90.3 %
LODDS3 34 (42.0 %) 35.3 %
LODDS4 13 (16.0 %) 0.0 %
Retrieved LN (15–25) 405
Seventh UICC pN staging 101.302 <0.001
pN0 164 (40.5 %) 79.9 %
pN1 77 (40.5 %) 57.1 %
pN2 104 (25.7 %) 41.3 %
pN3 60 (14.8 %) 18.3 %
pN ratio 117.273 <0.001
rN0 164 (40.5 %) 79.9 %
rN1 62 (15.3 %) 61.3 %
rN2 96 (23.7 %) 47.9 %
rN3 83 (20.5 %) 16.9 %
LODDS 135.377 <0.001
LODDS1 147 (36.3 %) 85.7 %
LODDS2 48 (11.9 %) 52.1 %
LODDS3 175 (43.2 %) 42.3 %
LODDS4 35 (8.6 %) 11.4 %




χ2 value P value
Seventh UICC pN staging 150.634 <0.001
pN0 119 (33.4 %) 84.0 %
pN1 53 (14.9 %) 71.6 %
pN2 60 (16.9 %) 46.7 %
pN3 124 (34.8 %) 17.7 %
pN ratio 160.727 <0.001
rN0 119 (33.4 %) 84.0 %
rN1 69 (19.4 %) 68.1 %
rN2 67 (18.8 %) 40.3 %
rN3 101 (28.4 %) 13.9 %
LODDS 173.033 <0.001
LODDS1 123 (34.6 %) 87.8 %
LODDS2 49 (13.8 %) 57.1 %
LODDS3 141 (39.6 %) 34.8 %
LODDS4 43 (12.1 %) 7.0 %
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first to compare the above three conditions among the pN, LNR
and LODDS systems. In multivariate Cox regression analysis
in the present study, the pN, LNR and LODDS systemswere all
found to be independent parameters for overall survival.
Moreover, the LODDS system had the highest linear trend χ2
score, likelihood ratio (χ2) test score, largest AUC and lowest
AIC value, indicating that the LODDS system was superior to
both the pN system and LNR system.
Theoretically, the LODDS system was superior to the pN
system in minimising stage migration, particularly in cases
where the number of analysed lymph nodes was insufficient
[22]. We further interpret that this novel system had a remark-
able robustness in terms of the prognostic effect and discrim-
ination ability at different levels of tested lymph nodes. As
shown in Table 5, when the number of retrieved lymph nodes
was insufficient (≤10 or 11–14), the LODDS system had the
best performance in homogeneity, discriminatory ability,
monotonicity of gradients and accuracy of the prognosis eval-
uation, followed by the LNR system and pN system.
Moreover, in the present study, the pN and LNR systems were
positively correlated with the number of retrieved lymph
nodes. However, unlike that reported in the study of Qiu
[11], we found that there was no relationship between the
number of tested lymph nodes and the LODDS system, indi-
cating that the LNR and pN systems were affected by the total
number of tested lymph nodes, whereas the LODDS system
was unaffected. Moreover, Aurello [23] reported that the
LODDS system was a function of the number of negative
lymph nodes, whereas the LNR system was a function of the
number of total retrieved lymph nodes; hence, theoretically,
the LODDS systemwas superior to the LNR system. Jiao [24]
explained that cases with an increasing number of tested
lymph nodes may reflect better survival, particularly in pa-
tients with node-negative gastric cancer. For patients with an
LNR value 0 or 1, the LNR system had no discriminatory
power. As shown in Fig. 2b, the LODDS system can distin-
guish patients with an LNR value 0 or 1, which accounted for
39.6 % of the total number of patients. Moreover, using the
log-rank test, we noted that LODDS had the ability to distin-
guish between patients with different pN or LNR systems into
distinct prognostic groups. This evidence strongly suggests
that the LODDS system may be the most reliable method for
lymph node classification in gastric cancer.
Our study had certain limitations. First, all data was obtain-
ed from a single institution, and this may not reflect the status
Table 6 Comparison of prognostic value of the different pN staging










Seventh UICC pN 9.577 9.776 410.023 0.669
rN 28.113 38.959 384.198 0.792
LODDS 29.657 64.653 370.819 0.804
Retrieved LN (11–14)
Seventh UICC pN 24.720 33.769 306.713 0.829
rN 39.795 61.343 292.089 0.889
LODDS 49.661 65.832 290.830 0.877
Retrieved LN (15–25)
Seventh UICC pN 80.198 101.110 2109.785 0.747
rN 88.779 117.045 2099.359 0.760
LODDS 95.421 135.126 2082.645 0.763
Retrieved LN (>25)
Seventh UICC pN 111.970 150.229 1851.248 0.809
rN 113.450 160.300 1848.628 0.813
LODDS 114.897 172.573 1840.384 0.810
Table 7 Survival analysis of pN stage and rN systems according to the
LODDS staging system
Number 5-year survival rate χ2 value P value
UICC pN
UICC pN0 22.895 <0.001
LODDS1 267 (73.4 %) 89.9 %
LODDS2 97 (26.6 %) 67.0 %
UICC pN1 28.892 <0.001
LODDS1 10 (5.8 %) 90.0 %
LODDS2 68 (39.3 %) 64.7 %
LODDS3 94 (54.3 %) 46.8 %
LODDS4 1 (0.6 %) 0.0 %
UICC pN2 11.004 0.004
LODDS2 6 (3.0 %) 83.3 %
LODDS3 184 (92.9 %) 40.2 %
LODDS4 8 (4.1 %) 12.5 %
UICC pN3 17.658 <0.001
LODDS3 106 (53.0 %) 26.8 %
LODDS4 94 (47.0 %) 9.6 %
rN
rN0 22.895 <0.001
LODDS1 267 (73.4 %) 89.9 %
LODDS2 97 (26.6 %) 67.0 %
rN1 9.265 0.010
LODDS1 10 (6.8 %) 90.0 %
LODDS2 74 (50.7 %) 69.2 %
LODDS3 62 (42.5 %) 50.4 %
rN2 6.366 0.012
LODDS2 19 (9.7 %) 73.7 %
LODDS3 177 (90.3 %) 40.1 %
rN3 22.961 <0.001
LODDS3 126 (55.0 %) 17.6 %
LODDS4 103 (45.0 %) 9.7 %
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in other centres in China. Moreover, the method of calculation
in the LODDS system was complicated, which may limit the
clinical application of the LODDS system.
In conclusion, the pN, LNR and LODDS systems appear to
be independent prognostic factors, as determined by the multi-
variate analysis. Although the LODDS system was more com-
plex, it showed prognostic superiority over both the pN and
LNR systems in our study. It can discriminate survival differ-
ences of gastric cancer patients with negative lymph nodes and
an insufficient number of retrieved lymph nodes. Hence, the
LODDS system should be considered as a novel and promising
lymph node staging system for gastric cancer in the future.
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